cd4 antibody Search Results


96
Miltenyi Biotec anti cd4
Anti Cd4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd4/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
anti cd4 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
R&D Systems goat polyclonal antibodies against human p55
Goat Polyclonal Antibodies Against Human P55, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat polyclonal antibodies against human p55/product/R&D Systems
Average 94 stars, based on 1 article reviews
goat polyclonal antibodies against human p55 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

95
Miltenyi Biotec anti cd4 percp
Anti Cd4 Percp, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd4 percp/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
anti cd4 percp - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

95
Miltenyi Biotec anti cd4 apc
Anti Cd4 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd4 apc/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
anti cd4 apc - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

96
Proteintech mouse anti cd4
Mouse Anti Cd4, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti cd4/product/Proteintech
Average 96 stars, based on 1 article reviews
mouse anti cd4 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec human cd4
Human Cd4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd4/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
human cd4 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec anti mouse cd4 macs microbeads
Anti Mouse Cd4 Macs Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse cd4 macs microbeads/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
anti mouse cd4 macs microbeads - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

89
Sino Biological apc conjugated anti cd4
Apc Conjugated Anti Cd4, supplied by Sino Biological, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc conjugated anti cd4/product/Sino Biological
Average 89 stars, based on 1 article reviews
apc conjugated anti cd4 - by Bioz Stars, 2026-03
89/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd4 fitc
A technical control of non-stimulated (NST) PMBCs was included. a, b, c) Percentage <t>CD4</t> T cells in PBMCs stimulated with S peptides in the H donors (a) and in O patients (b). c) Comparison between H donors and O patients. d, e, f) Percentage CD4 T cells in PBMCs stimulated with M peptides in H donors (d) and in O patients (e). f) Comparison between H donors and O patients. g, h, i) Percentage CD4 T cells in PBMCs stimulated with N peptides in the H donors (g) and in O patients (h). i) Comparison between H donors and O patients. a-i) Krustal-Wallis test followed by Dunn’s test for pair-wise comparisons was employed. j) Dot plot of the percentage of S and M-specific CD4 T cells. The U of Mann-Whitney was used to test differences. k) Dot plot of S- and M-specific CD4 T cells in vaccinated H donors, from samples collected at the indicated timelines. Pair-wise comparisons were performed using the U of Mann-Whitney. l, m) Relative percentages of CD4 T cell differentiation phenotypes in H donors (l) and O patients (m) . N, CM, EM and E, indicate naïve-stem cell (CD62L+ CD45RA+), central memory (CD62L+ CD45RA-), effector memory (CD62L- CD45RA-) and effector (CD62L-CD45RA+) phenotypes. Relevant statistical comparisons are detailed in . *, **, ***, **** indicate P <0.05, <0.01, <0.001 and <0.0001, respectively.
Cd4 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd4 fitc/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd4 fitc - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd4 antibody
(A) Schematic of experimental design. (B) Flow cytometry contour plots demonstrating the loss of the endogenous splenic <t>CD4</t> + Foxp3 -GFP + Treg population in Foxp3 GFP-DTR mice following administration of diphtheria toxin (DTx). (C) Lung and spleen Foxp3 -GFP + Treg cell quantification in Foxp3 GFP-DTR mice that received influenza A virus but no DTx (No DTx + flu, n = 3) or influenza and DTx (DTx + flu, n = 4) at 13 DPI compared with mice that received DTx but no influenza (DTx No flu, n = 3). (D) Mass over time of Foxp3 GFP-DTR mice receiving no DTx or DTx until pre-specified timepoints (DTx withdrawal) following intra-tracheal inoculation of 5 plaque-forming units (PFU) of influenza A/WSN/33 H1N1 virus (n = 5 per group). (E) Representative lung histopathology (H&E staining) at 60 DPI of control (No DTx) and DTx withdrawal mice following influenza A virus infection. Original magnification x10, scale bar = 1 mm. (F) Metagene analysis of DNA methylation across Treg-SE of Tregs recovered from the mice described in 1D compared with splenic nTregs and iTregs from culture. Data presented as mean and SD. * q < 0.05 according to one-way ANOVA with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (C).* q < 0.05 according to mixed-effects model (REML) with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (D).
Cd4 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd4 antibody/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd4 antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

93
R&D Systems goat anti mouse cd4
(A) Schematic of experimental design. (B) Flow cytometry contour plots demonstrating the loss of the endogenous splenic <t>CD4</t> + Foxp3 -GFP + Treg population in Foxp3 GFP-DTR mice following administration of diphtheria toxin (DTx). (C) Lung and spleen Foxp3 -GFP + Treg cell quantification in Foxp3 GFP-DTR mice that received influenza A virus but no DTx (No DTx + flu, n = 3) or influenza and DTx (DTx + flu, n = 4) at 13 DPI compared with mice that received DTx but no influenza (DTx No flu, n = 3). (D) Mass over time of Foxp3 GFP-DTR mice receiving no DTx or DTx until pre-specified timepoints (DTx withdrawal) following intra-tracheal inoculation of 5 plaque-forming units (PFU) of influenza A/WSN/33 H1N1 virus (n = 5 per group). (E) Representative lung histopathology (H&E staining) at 60 DPI of control (No DTx) and DTx withdrawal mice following influenza A virus infection. Original magnification x10, scale bar = 1 mm. (F) Metagene analysis of DNA methylation across Treg-SE of Tregs recovered from the mice described in 1D compared with splenic nTregs and iTregs from culture. Data presented as mean and SD. * q < 0.05 according to one-way ANOVA with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (C).* q < 0.05 according to mixed-effects model (REML) with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (D).
Goat Anti Mouse Cd4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti mouse cd4/product/R&D Systems
Average 93 stars, based on 1 article reviews
goat anti mouse cd4 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

95
Miltenyi Biotec anti human cd8 anti human cd4 antibody coated beads
(A) Schematic of experimental design. (B) Flow cytometry contour plots demonstrating the loss of the endogenous splenic <t>CD4</t> + Foxp3 -GFP + Treg population in Foxp3 GFP-DTR mice following administration of diphtheria toxin (DTx). (C) Lung and spleen Foxp3 -GFP + Treg cell quantification in Foxp3 GFP-DTR mice that received influenza A virus but no DTx (No DTx + flu, n = 3) or influenza and DTx (DTx + flu, n = 4) at 13 DPI compared with mice that received DTx but no influenza (DTx No flu, n = 3). (D) Mass over time of Foxp3 GFP-DTR mice receiving no DTx or DTx until pre-specified timepoints (DTx withdrawal) following intra-tracheal inoculation of 5 plaque-forming units (PFU) of influenza A/WSN/33 H1N1 virus (n = 5 per group). (E) Representative lung histopathology (H&E staining) at 60 DPI of control (No DTx) and DTx withdrawal mice following influenza A virus infection. Original magnification x10, scale bar = 1 mm. (F) Metagene analysis of DNA methylation across Treg-SE of Tregs recovered from the mice described in 1D compared with splenic nTregs and iTregs from culture. Data presented as mean and SD. * q < 0.05 according to one-way ANOVA with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (C).* q < 0.05 according to mixed-effects model (REML) with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (D).
Anti Human Cd8 Anti Human Cd4 Antibody Coated Beads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd8 anti human cd4 antibody coated beads/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
anti human cd8 anti human cd4 antibody coated beads - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


A technical control of non-stimulated (NST) PMBCs was included. a, b, c) Percentage CD4 T cells in PBMCs stimulated with S peptides in the H donors (a) and in O patients (b). c) Comparison between H donors and O patients. d, e, f) Percentage CD4 T cells in PBMCs stimulated with M peptides in H donors (d) and in O patients (e). f) Comparison between H donors and O patients. g, h, i) Percentage CD4 T cells in PBMCs stimulated with N peptides in the H donors (g) and in O patients (h). i) Comparison between H donors and O patients. a-i) Krustal-Wallis test followed by Dunn’s test for pair-wise comparisons was employed. j) Dot plot of the percentage of S and M-specific CD4 T cells. The U of Mann-Whitney was used to test differences. k) Dot plot of S- and M-specific CD4 T cells in vaccinated H donors, from samples collected at the indicated timelines. Pair-wise comparisons were performed using the U of Mann-Whitney. l, m) Relative percentages of CD4 T cell differentiation phenotypes in H donors (l) and O patients (m) . N, CM, EM and E, indicate naïve-stem cell (CD62L+ CD45RA+), central memory (CD62L+ CD45RA-), effector memory (CD62L- CD45RA-) and effector (CD62L-CD45RA+) phenotypes. Relevant statistical comparisons are detailed in . *, **, ***, **** indicate P <0.05, <0.01, <0.001 and <0.0001, respectively.

Journal: medRxiv

Article Title: Profiling of immune responses to COVID-19 and vaccination uncovers potent adjuvant capacities of SARS CoV-2 infection to vaccination leading to memory T cell responses with a Th17 signature in cancer patients

doi: 10.1101/2022.05.27.22275672

Figure Lengend Snippet: A technical control of non-stimulated (NST) PMBCs was included. a, b, c) Percentage CD4 T cells in PBMCs stimulated with S peptides in the H donors (a) and in O patients (b). c) Comparison between H donors and O patients. d, e, f) Percentage CD4 T cells in PBMCs stimulated with M peptides in H donors (d) and in O patients (e). f) Comparison between H donors and O patients. g, h, i) Percentage CD4 T cells in PBMCs stimulated with N peptides in the H donors (g) and in O patients (h). i) Comparison between H donors and O patients. a-i) Krustal-Wallis test followed by Dunn’s test for pair-wise comparisons was employed. j) Dot plot of the percentage of S and M-specific CD4 T cells. The U of Mann-Whitney was used to test differences. k) Dot plot of S- and M-specific CD4 T cells in vaccinated H donors, from samples collected at the indicated timelines. Pair-wise comparisons were performed using the U of Mann-Whitney. l, m) Relative percentages of CD4 T cell differentiation phenotypes in H donors (l) and O patients (m) . N, CM, EM and E, indicate naïve-stem cell (CD62L+ CD45RA+), central memory (CD62L+ CD45RA-), effector memory (CD62L- CD45RA-) and effector (CD62L-CD45RA+) phenotypes. Relevant statistical comparisons are detailed in . *, **, ***, **** indicate P <0.05, <0.01, <0.001 and <0.0001, respectively.

Article Snippet: The following fluorochrome-conjugated antibodies were used: CD14-Violet Fluor 450 (Ref 75-0149-T100, TONBO), CD11b-PerCP-Cy5-5 (Ref 65-0112-U1, TONBO), CD62L-APC (Ref 130-113-617, Miltenyi), CD66b-APC-Cy7 (Ref 130-120-146, Miltenyi), CD54-FITC (Ref 130-104-214, Miltenyi), CD19-PE (Ref 130-113-731, Miltenyi), CD3-APC (Ref 130-113-135, Miltenyi), CD8-APC-Cy7 (Ref 130-110-681, Miltenyi), CD4-FITC (Ref 130-114-531, Miltenyi), CD27-PE (Ref 50-0279-T100, TONBO), CD28-PE-Cy7 (Ref 130-126-316, Miltenyi).

Techniques: Control, Comparison, MANN-WHITNEY, Cell Differentiation

Representative flow cytometry density plots of CD154 and CD137 co-expression profiles in CD4 T cells from donors before and after stimulation with S-peptides, as indicated.

Journal: medRxiv

Article Title: Profiling of immune responses to COVID-19 and vaccination uncovers potent adjuvant capacities of SARS CoV-2 infection to vaccination leading to memory T cell responses with a Th17 signature in cancer patients

doi: 10.1101/2022.05.27.22275672

Figure Lengend Snippet: Representative flow cytometry density plots of CD154 and CD137 co-expression profiles in CD4 T cells from donors before and after stimulation with S-peptides, as indicated.

Article Snippet: The following fluorochrome-conjugated antibodies were used: CD14-Violet Fluor 450 (Ref 75-0149-T100, TONBO), CD11b-PerCP-Cy5-5 (Ref 65-0112-U1, TONBO), CD62L-APC (Ref 130-113-617, Miltenyi), CD66b-APC-Cy7 (Ref 130-120-146, Miltenyi), CD54-FITC (Ref 130-104-214, Miltenyi), CD19-PE (Ref 130-113-731, Miltenyi), CD3-APC (Ref 130-113-135, Miltenyi), CD8-APC-Cy7 (Ref 130-110-681, Miltenyi), CD4-FITC (Ref 130-114-531, Miltenyi), CD27-PE (Ref 50-0279-T100, TONBO), CD28-PE-Cy7 (Ref 130-126-316, Miltenyi).

Techniques: Flow Cytometry, Expressing

a) Representative flow cytometry density plots with CD62L-CD45RA co-expression profiles in CD4 T cells before and after the stimulation with S-peptides. Quadrants were established with unstained controls. Percentages of the corresponding populations are shown within the quadrants. b , c) CD4 T cell phenotypic changes in H-V (b) and H-CoV-V (c) donors. (-) and (+S), non-stimulated and S-peptide stimulation. N, CM, EM and E, indicate naïve-stem cell (CD62L+ CD45RA+), central memory (CD62L+ CD45RA-), effector memory (CD62L- CD45RA-) and effector (CD62L-CD45RA+) phenotypes. d) Phenotypic changes in CD4 T cells within O-CoV-V before and after stimulation with S-peptides. e , f) Effects of previous CoV infection in vaccinated H donors and O patients over T cell phenotypes after stimulation with S-peptides. b-f) Relevant statistical comparisons are indicated by ANOVA followed by pair-wise comparisons with Tukey’s test. g , h) Relative percentages of CD4 T cell differentiation phenotypes in H-V and O-V (g) and in H-CoV-V and O-CoV-V (h) CD27+ CD28+, CD27-CD28+ and CD27+ CD28+ indicate poorly differentiated, intermediate differentiated and highly differentiated T cell phenotypes. U of Mann-Whitney was used to test for significance.*, **, *** indicate significant (P<0.05), very significant (P<0.01) and highly significant (P<0.001) differences.

Journal: medRxiv

Article Title: Profiling of immune responses to COVID-19 and vaccination uncovers potent adjuvant capacities of SARS CoV-2 infection to vaccination leading to memory T cell responses with a Th17 signature in cancer patients

doi: 10.1101/2022.05.27.22275672

Figure Lengend Snippet: a) Representative flow cytometry density plots with CD62L-CD45RA co-expression profiles in CD4 T cells before and after the stimulation with S-peptides. Quadrants were established with unstained controls. Percentages of the corresponding populations are shown within the quadrants. b , c) CD4 T cell phenotypic changes in H-V (b) and H-CoV-V (c) donors. (-) and (+S), non-stimulated and S-peptide stimulation. N, CM, EM and E, indicate naïve-stem cell (CD62L+ CD45RA+), central memory (CD62L+ CD45RA-), effector memory (CD62L- CD45RA-) and effector (CD62L-CD45RA+) phenotypes. d) Phenotypic changes in CD4 T cells within O-CoV-V before and after stimulation with S-peptides. e , f) Effects of previous CoV infection in vaccinated H donors and O patients over T cell phenotypes after stimulation with S-peptides. b-f) Relevant statistical comparisons are indicated by ANOVA followed by pair-wise comparisons with Tukey’s test. g , h) Relative percentages of CD4 T cell differentiation phenotypes in H-V and O-V (g) and in H-CoV-V and O-CoV-V (h) CD27+ CD28+, CD27-CD28+ and CD27+ CD28+ indicate poorly differentiated, intermediate differentiated and highly differentiated T cell phenotypes. U of Mann-Whitney was used to test for significance.*, **, *** indicate significant (P<0.05), very significant (P<0.01) and highly significant (P<0.001) differences.

Article Snippet: The following fluorochrome-conjugated antibodies were used: CD14-Violet Fluor 450 (Ref 75-0149-T100, TONBO), CD11b-PerCP-Cy5-5 (Ref 65-0112-U1, TONBO), CD62L-APC (Ref 130-113-617, Miltenyi), CD66b-APC-Cy7 (Ref 130-120-146, Miltenyi), CD54-FITC (Ref 130-104-214, Miltenyi), CD19-PE (Ref 130-113-731, Miltenyi), CD3-APC (Ref 130-113-135, Miltenyi), CD8-APC-Cy7 (Ref 130-110-681, Miltenyi), CD4-FITC (Ref 130-114-531, Miltenyi), CD27-PE (Ref 50-0279-T100, TONBO), CD28-PE-Cy7 (Ref 130-126-316, Miltenyi).

Techniques: Flow Cytometry, Expressing, Infection, Cell Differentiation, MANN-WHITNEY

a) Representative flow cytometry density plots with the expression of INFγ and IL-17 before and after stimulation with S peptides in CD4 T cells. b) In CD8 T cells.

Journal: medRxiv

Article Title: Profiling of immune responses to COVID-19 and vaccination uncovers potent adjuvant capacities of SARS CoV-2 infection to vaccination leading to memory T cell responses with a Th17 signature in cancer patients

doi: 10.1101/2022.05.27.22275672

Figure Lengend Snippet: a) Representative flow cytometry density plots with the expression of INFγ and IL-17 before and after stimulation with S peptides in CD4 T cells. b) In CD8 T cells.

Article Snippet: The following fluorochrome-conjugated antibodies were used: CD14-Violet Fluor 450 (Ref 75-0149-T100, TONBO), CD11b-PerCP-Cy5-5 (Ref 65-0112-U1, TONBO), CD62L-APC (Ref 130-113-617, Miltenyi), CD66b-APC-Cy7 (Ref 130-120-146, Miltenyi), CD54-FITC (Ref 130-104-214, Miltenyi), CD19-PE (Ref 130-113-731, Miltenyi), CD3-APC (Ref 130-113-135, Miltenyi), CD8-APC-Cy7 (Ref 130-110-681, Miltenyi), CD4-FITC (Ref 130-114-531, Miltenyi), CD27-PE (Ref 50-0279-T100, TONBO), CD28-PE-Cy7 (Ref 130-126-316, Miltenyi).

Techniques: Flow Cytometry, Expressing

a, b, c) Percentage of IFNγ-CD4 T cells specific for the S protein in H and O groups. d, e, f) Percentage of IFNγ-CD4 T cells specific for the M protein in H and O groups. g, h, i) Percentage of IL17-CD4 T cells specific for the S protein in H and O groups. j, k, l) Percentage of IL17-CD4 T cells specific for the M protein in H and O groups. a-l) Statistical significance was evaluated with Kruskal-Wallis followed by Dunn’s pair-wise comparisons. m, n) Percentage of CD4 T cells expressing IL-17 and IFNγ expression in H-V donors that completed the vaccine regime before sample collection in the indicated timelines, for both S and M proteins. Significance was tested with the U of Mann-Whitney test. NST, technical control of non-stimulated PMBCs. *, **, *** indicate significant (P<0.05), very significant (P<0.01) and highly significant (P<0.001) differences.

Journal: medRxiv

Article Title: Profiling of immune responses to COVID-19 and vaccination uncovers potent adjuvant capacities of SARS CoV-2 infection to vaccination leading to memory T cell responses with a Th17 signature in cancer patients

doi: 10.1101/2022.05.27.22275672

Figure Lengend Snippet: a, b, c) Percentage of IFNγ-CD4 T cells specific for the S protein in H and O groups. d, e, f) Percentage of IFNγ-CD4 T cells specific for the M protein in H and O groups. g, h, i) Percentage of IL17-CD4 T cells specific for the S protein in H and O groups. j, k, l) Percentage of IL17-CD4 T cells specific for the M protein in H and O groups. a-l) Statistical significance was evaluated with Kruskal-Wallis followed by Dunn’s pair-wise comparisons. m, n) Percentage of CD4 T cells expressing IL-17 and IFNγ expression in H-V donors that completed the vaccine regime before sample collection in the indicated timelines, for both S and M proteins. Significance was tested with the U of Mann-Whitney test. NST, technical control of non-stimulated PMBCs. *, **, *** indicate significant (P<0.05), very significant (P<0.01) and highly significant (P<0.001) differences.

Article Snippet: The following fluorochrome-conjugated antibodies were used: CD14-Violet Fluor 450 (Ref 75-0149-T100, TONBO), CD11b-PerCP-Cy5-5 (Ref 65-0112-U1, TONBO), CD62L-APC (Ref 130-113-617, Miltenyi), CD66b-APC-Cy7 (Ref 130-120-146, Miltenyi), CD54-FITC (Ref 130-104-214, Miltenyi), CD19-PE (Ref 130-113-731, Miltenyi), CD3-APC (Ref 130-113-135, Miltenyi), CD8-APC-Cy7 (Ref 130-110-681, Miltenyi), CD4-FITC (Ref 130-114-531, Miltenyi), CD27-PE (Ref 50-0279-T100, TONBO), CD28-PE-Cy7 (Ref 130-126-316, Miltenyi).

Techniques: Expressing, MANN-WHITNEY, Control

(A) Schematic of experimental design. (B) Flow cytometry contour plots demonstrating the loss of the endogenous splenic CD4 + Foxp3 -GFP + Treg population in Foxp3 GFP-DTR mice following administration of diphtheria toxin (DTx). (C) Lung and spleen Foxp3 -GFP + Treg cell quantification in Foxp3 GFP-DTR mice that received influenza A virus but no DTx (No DTx + flu, n = 3) or influenza and DTx (DTx + flu, n = 4) at 13 DPI compared with mice that received DTx but no influenza (DTx No flu, n = 3). (D) Mass over time of Foxp3 GFP-DTR mice receiving no DTx or DTx until pre-specified timepoints (DTx withdrawal) following intra-tracheal inoculation of 5 plaque-forming units (PFU) of influenza A/WSN/33 H1N1 virus (n = 5 per group). (E) Representative lung histopathology (H&E staining) at 60 DPI of control (No DTx) and DTx withdrawal mice following influenza A virus infection. Original magnification x10, scale bar = 1 mm. (F) Metagene analysis of DNA methylation across Treg-SE of Tregs recovered from the mice described in 1D compared with splenic nTregs and iTregs from culture. Data presented as mean and SD. * q < 0.05 according to one-way ANOVA with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (C).* q < 0.05 according to mixed-effects model (REML) with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (D).

Journal: bioRxiv

Article Title: Maintenance DNA methylation is required for induced regulatory T cell reparative function following viral pneumonia

doi: 10.1101/2025.02.25.640199

Figure Lengend Snippet: (A) Schematic of experimental design. (B) Flow cytometry contour plots demonstrating the loss of the endogenous splenic CD4 + Foxp3 -GFP + Treg population in Foxp3 GFP-DTR mice following administration of diphtheria toxin (DTx). (C) Lung and spleen Foxp3 -GFP + Treg cell quantification in Foxp3 GFP-DTR mice that received influenza A virus but no DTx (No DTx + flu, n = 3) or influenza and DTx (DTx + flu, n = 4) at 13 DPI compared with mice that received DTx but no influenza (DTx No flu, n = 3). (D) Mass over time of Foxp3 GFP-DTR mice receiving no DTx or DTx until pre-specified timepoints (DTx withdrawal) following intra-tracheal inoculation of 5 plaque-forming units (PFU) of influenza A/WSN/33 H1N1 virus (n = 5 per group). (E) Representative lung histopathology (H&E staining) at 60 DPI of control (No DTx) and DTx withdrawal mice following influenza A virus infection. Original magnification x10, scale bar = 1 mm. (F) Metagene analysis of DNA methylation across Treg-SE of Tregs recovered from the mice described in 1D compared with splenic nTregs and iTregs from culture. Data presented as mean and SD. * q < 0.05 according to one-way ANOVA with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (C).* q < 0.05 according to mixed-effects model (REML) with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (D).

Article Snippet: For iTreg cell sorting, the single-cell suspension was enriched using a CD4 + antibody (Miltenyi cat. no. 130-101-962) and the lungs were stained using the reagents listed in .

Techniques: Flow Cytometry, Virus, Histopathology, Staining, Control, Infection, DNA Methylation Assay

(A) Flow cytometry contour plots for phenotyping of the CD4 + Foxp3 -GFP + tdTomato + iTreg population following culture in the presence of αCD3/αCD28, IL-2, TGF-β, and tamoxifen. (B) Mass over time of Foxp3 GFP-DTR mice receiving adoptive transfer of nTreg (n = 27), PBS (n = 21), Tconv (n = 25), or iTreg (n = 18) cells 5 days following intra-tracheal inoculation of 6.5 PFU of influenza A/WSN/33 H1N1 virus. Negative controls included mice that received influenza but no DTx (no DTx + flu, n = 9) and DTx but no influenza (DTx no flu, n = 3). (C) Total number of lung CD45 + cells at 24 DPI in mice that received No DTx (n = 3), nTreg (n = 15), PBS (n = 11), or Tconv (n = 10). (D-H) Total number of lung CD326 + CD31 − CD45 − cells (D), CD326 + MHCII + T1A − cells (E), KRT5 + CD326 + cells (F), Ki-67 + CD326 + MHCII + cells (G), and CD326 − CD31 + cells (H) at 24 DPI in mice that received No DTx (n = 3), nTreg (n = 15), PBS (n = 11), or Tconv (n = 10) cells. * q < 0.05 according to mixed-effects model (REML) with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (B). Data presented as mean and SD (C, F-H) with * q < 0.05 according to multiple Mann-Whitney tests and correcting for multiple comparisons using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (C). UHRF1 is dispensable for iTreg FOXP3 induction and stability but is required to maintain transcriptional and epigenetic programs in vitro .

Journal: bioRxiv

Article Title: Maintenance DNA methylation is required for induced regulatory T cell reparative function following viral pneumonia

doi: 10.1101/2025.02.25.640199

Figure Lengend Snippet: (A) Flow cytometry contour plots for phenotyping of the CD4 + Foxp3 -GFP + tdTomato + iTreg population following culture in the presence of αCD3/αCD28, IL-2, TGF-β, and tamoxifen. (B) Mass over time of Foxp3 GFP-DTR mice receiving adoptive transfer of nTreg (n = 27), PBS (n = 21), Tconv (n = 25), or iTreg (n = 18) cells 5 days following intra-tracheal inoculation of 6.5 PFU of influenza A/WSN/33 H1N1 virus. Negative controls included mice that received influenza but no DTx (no DTx + flu, n = 9) and DTx but no influenza (DTx no flu, n = 3). (C) Total number of lung CD45 + cells at 24 DPI in mice that received No DTx (n = 3), nTreg (n = 15), PBS (n = 11), or Tconv (n = 10). (D-H) Total number of lung CD326 + CD31 − CD45 − cells (D), CD326 + MHCII + T1A − cells (E), KRT5 + CD326 + cells (F), Ki-67 + CD326 + MHCII + cells (G), and CD326 − CD31 + cells (H) at 24 DPI in mice that received No DTx (n = 3), nTreg (n = 15), PBS (n = 11), or Tconv (n = 10) cells. * q < 0.05 according to mixed-effects model (REML) with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (B). Data presented as mean and SD (C, F-H) with * q < 0.05 according to multiple Mann-Whitney tests and correcting for multiple comparisons using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% (C). UHRF1 is dispensable for iTreg FOXP3 induction and stability but is required to maintain transcriptional and epigenetic programs in vitro .

Article Snippet: For iTreg cell sorting, the single-cell suspension was enriched using a CD4 + antibody (Miltenyi cat. no. 130-101-962) and the lungs were stained using the reagents listed in .

Techniques: Flow Cytometry, Adoptive Transfer Assay, Virus, MANN-WHITNEY, In Vitro

(A) Schematic of experimental design. (B) Frequency of Foxp3 -GFP + and Foxp3 -GFP − tdTomato + (ex-FOXP3) cells in culture of iTregs with UHRF1 deleted concurrent with (early) or 5 days after (delayed) FOXP3 induction compared with Uhrf1 +/+ controls on days 5 and 12 of culture (n = 3 per group). (C) Division index of CD4 + CTV + Foxp3 -GFP − splenic responder T cells co-cultured for 72 hours with varying ratios of Uhrf1 +/+ CD4 + Foxp3 -GFP + iTregs, Uhrf1 fl/fl CD4 + Foxp3 -GFP + iTregs, or Uhrf1 +/+ nTregs (n = 3 per group). (D) Principal component analysis of 6,978 differentially expressed genes from sorted cells described in A, identified from ANOVA-like testing with FDR q < 0.05. Ellipses represent normal contour lines with 1 standard deviation probability. (E) K-means clustering of 127 genes with an FDR q < 0.05 comparing the Uhrf1 fl/fl and Uhrf1 +/+ iTreg populations on day 12 in which UHRF1 was deleted after FOXP3 induction (delayed) with k = 2. (F) MA plot comparing gene expression of delayed Uhrf1 +/+ and Uhrf1 fl/fl iTregs on day 12 of culture. Genes of interest are annotated. (G) Enrichment plot of the GSE14415_INDUCED_TREG_VS_TCONV_UP, GSE14415_INDUCED_TREG_VS_TCONV_DN, GSE14415_INDUCED_TREG_VS_FAILED_INDUCED_TREG_UP, GSE37605_TREG_VS_TCONV_C57BL6_FOXP3_FUSION_GFP_UP, GSE13306_TREG_VS_TCONV_UP gene sets ( p < 0.05, FDR q < 0.25) generated through GSEA preranked testing of the expressed genes of delayed Uhrf1 +/+ iTregs (control) and delayed Uhrf1 fl/fl iTregs on day 12 of culture. (H) PCA of 81,179 differentially methylated cytosines identified from ANOVA-like testing with FDR q < 0.05. Ellipses represent normal contour lines with 1 standard deviation probability. (I) Cumulative distribution function plot of differentially methylated cytosines expressed as β scores, with 0 representing unmethylated and 1 representing fully methylated; a shift in the cumulative distribution function up and to the left represents relative hypomethylation. * q < 0.05 according to two-way ANOVA with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5.

Journal: bioRxiv

Article Title: Maintenance DNA methylation is required for induced regulatory T cell reparative function following viral pneumonia

doi: 10.1101/2025.02.25.640199

Figure Lengend Snippet: (A) Schematic of experimental design. (B) Frequency of Foxp3 -GFP + and Foxp3 -GFP − tdTomato + (ex-FOXP3) cells in culture of iTregs with UHRF1 deleted concurrent with (early) or 5 days after (delayed) FOXP3 induction compared with Uhrf1 +/+ controls on days 5 and 12 of culture (n = 3 per group). (C) Division index of CD4 + CTV + Foxp3 -GFP − splenic responder T cells co-cultured for 72 hours with varying ratios of Uhrf1 +/+ CD4 + Foxp3 -GFP + iTregs, Uhrf1 fl/fl CD4 + Foxp3 -GFP + iTregs, or Uhrf1 +/+ nTregs (n = 3 per group). (D) Principal component analysis of 6,978 differentially expressed genes from sorted cells described in A, identified from ANOVA-like testing with FDR q < 0.05. Ellipses represent normal contour lines with 1 standard deviation probability. (E) K-means clustering of 127 genes with an FDR q < 0.05 comparing the Uhrf1 fl/fl and Uhrf1 +/+ iTreg populations on day 12 in which UHRF1 was deleted after FOXP3 induction (delayed) with k = 2. (F) MA plot comparing gene expression of delayed Uhrf1 +/+ and Uhrf1 fl/fl iTregs on day 12 of culture. Genes of interest are annotated. (G) Enrichment plot of the GSE14415_INDUCED_TREG_VS_TCONV_UP, GSE14415_INDUCED_TREG_VS_TCONV_DN, GSE14415_INDUCED_TREG_VS_FAILED_INDUCED_TREG_UP, GSE37605_TREG_VS_TCONV_C57BL6_FOXP3_FUSION_GFP_UP, GSE13306_TREG_VS_TCONV_UP gene sets ( p < 0.05, FDR q < 0.25) generated through GSEA preranked testing of the expressed genes of delayed Uhrf1 +/+ iTregs (control) and delayed Uhrf1 fl/fl iTregs on day 12 of culture. (H) PCA of 81,179 differentially methylated cytosines identified from ANOVA-like testing with FDR q < 0.05. Ellipses represent normal contour lines with 1 standard deviation probability. (I) Cumulative distribution function plot of differentially methylated cytosines expressed as β scores, with 0 representing unmethylated and 1 representing fully methylated; a shift in the cumulative distribution function up and to the left represents relative hypomethylation. * q < 0.05 according to two-way ANOVA with two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5.

Article Snippet: For iTreg cell sorting, the single-cell suspension was enriched using a CD4 + antibody (Miltenyi cat. no. 130-101-962) and the lungs were stained using the reagents listed in .

Techniques: Cell Culture, Standard Deviation, Gene Expression, Generated, Control, Methylation

(A) MA plot comparing gene expression of Uhrf1 +/+ iTregs (control) with CD4 + Foxp3 -GFP + nTregs on day 5 of culture. Genes of interest are annotated. (B) Enrichment plots of the HALLMARK_MYC_TARGETS_V1, HALLMARK_E2F_TARGETS, HALLMARK_TGF_BETA_SIGNALING, HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_TNFA_SIGNALING_VIA_NFKB, HALLMARK_MTORC1_SIGNALING, HALLMARK_IL2_STAT5_SIGNALING, and HALLMARK_KRAS_SIGNALING_UP gene sets generated through GSEA preranked testing of the expressed genes of delayed Uhrf1 +/+ iTregs (control) and delayed Uhrf1 fl/fl iTregs on day 12 of culture.

Journal: bioRxiv

Article Title: Maintenance DNA methylation is required for induced regulatory T cell reparative function following viral pneumonia

doi: 10.1101/2025.02.25.640199

Figure Lengend Snippet: (A) MA plot comparing gene expression of Uhrf1 +/+ iTregs (control) with CD4 + Foxp3 -GFP + nTregs on day 5 of culture. Genes of interest are annotated. (B) Enrichment plots of the HALLMARK_MYC_TARGETS_V1, HALLMARK_E2F_TARGETS, HALLMARK_TGF_BETA_SIGNALING, HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_TNFA_SIGNALING_VIA_NFKB, HALLMARK_MTORC1_SIGNALING, HALLMARK_IL2_STAT5_SIGNALING, and HALLMARK_KRAS_SIGNALING_UP gene sets generated through GSEA preranked testing of the expressed genes of delayed Uhrf1 +/+ iTregs (control) and delayed Uhrf1 fl/fl iTregs on day 12 of culture.

Article Snippet: For iTreg cell sorting, the single-cell suspension was enriched using a CD4 + antibody (Miltenyi cat. no. 130-101-962) and the lungs were stained using the reagents listed in .

Techniques: Gene Expression, Control, Generated

(A-F) Total numbers of CD45 + (A), CD3 + (B), CD4 + CD8 − (C), CD4 − CD8 + (D), CD11b − CD64 + CD11c + SiglecF + (E), and CD11b + Ly6G + (F) cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 8), Tconv (n = 8), PBS (n = 8), Uhrf1 +/+ iTregs (n = 16), or U hrf1 fl/fl iTregs. (n = 16) (G) Total number of CD326 + CD31 − CD45 − (epithelial) cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 8), Tconv (n = 8), PBS (n = 7), Uhrf1 +/+ iTregs (n = 15), or U hrf1 fl/fl iTregs (n = 16). (H) Total number of KRT5 + CD326 + epithelial cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 7), Tconv (n = 7), PBS (n = 7), Uhrf1 +/+ iTregs (n = 13), or U hrf1 fl/fl iTregs (n = 14). (I) Total number of CD326 − CD31 + (endothelial) cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 8), Tconv (n = 8), PBS (n = 8), Uhrf1 +/+ iTregs (n = 14), or U hrf1 fl/fl iTregs (n = 15). Data presented as mean and SD. ns = not significant by multiple Mann-Whitney tests and correcting for multiple comparisons using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% test.

Journal: bioRxiv

Article Title: Maintenance DNA methylation is required for induced regulatory T cell reparative function following viral pneumonia

doi: 10.1101/2025.02.25.640199

Figure Lengend Snippet: (A-F) Total numbers of CD45 + (A), CD3 + (B), CD4 + CD8 − (C), CD4 − CD8 + (D), CD11b − CD64 + CD11c + SiglecF + (E), and CD11b + Ly6G + (F) cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 8), Tconv (n = 8), PBS (n = 8), Uhrf1 +/+ iTregs (n = 16), or U hrf1 fl/fl iTregs. (n = 16) (G) Total number of CD326 + CD31 − CD45 − (epithelial) cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 8), Tconv (n = 8), PBS (n = 7), Uhrf1 +/+ iTregs (n = 15), or U hrf1 fl/fl iTregs (n = 16). (H) Total number of KRT5 + CD326 + epithelial cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 7), Tconv (n = 7), PBS (n = 7), Uhrf1 +/+ iTregs (n = 13), or U hrf1 fl/fl iTregs (n = 14). (I) Total number of CD326 − CD31 + (endothelial) cells in the lungs at 11 DPI of Foxp3 GFP-DTR mice that received nTreg (n = 8), Tconv (n = 8), PBS (n = 8), Uhrf1 +/+ iTregs (n = 14), or U hrf1 fl/fl iTregs (n = 15). Data presented as mean and SD. ns = not significant by multiple Mann-Whitney tests and correcting for multiple comparisons using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 5% test.

Article Snippet: For iTreg cell sorting, the single-cell suspension was enriched using a CD4 + antibody (Miltenyi cat. no. 130-101-962) and the lungs were stained using the reagents listed in .

Techniques: MANN-WHITNEY